Filtrer vos résultats
- 4
- 4
- 4
- 1
- 2
- 1
- 4
- 2
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 4
- 3
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
|
|
triés par
|
Intra-arterial Idarubicin_lipiodol without embolization in hepatocellular carcinoma: the LIDA-B phase I trialJournal of Hepatology, 2018, 68 (6), pp.1163-1171. ⟨10.1016/j.jhep.2018.01.022⟩
Article dans une revue
hal-01707852v1
|
|||
Ipilimumab with atezolizumab-bevacizumab in patients with advanced hepatocellular carcinoma: The PRODIGE 81-FFCD 2101-TRIPLET-HCC trialDigestive and Liver Disease, 2023, ⟨10.1016/j.dld.2023.01.161⟩
Article dans une revue
hal-04016442v1
|
|||
Chemoembolization or Bland Embolization for Hepatocellular Carcinoma : The Question Is Still Unanswered.Journal of Clinical Oncology, 2017, 35 (2), pp.256 - 257. ⟨10.1200/JCO.2016.67.2915⟩
Article dans une revue
hal-01689472v1
|
|||
|
Liver chemoembolization of hepatocellular carcinoma using TANDEM ® microspheresFuture Oncology, 2018, 14 (26), pp.2761 - 2772. ⟨10.2217/fon-2018-0237⟩
Article dans une revue
hal-01921873v1
|